First Oral Weight-Loss Pill Hits TrumpRx at $149, Challenging Needle Drugs

Foundayo, the first GLP-1 weight-loss pill that can be swallowed with food, will list on President Trump’s price-comparison site TrumpRx as early as Thursday, a White House official told CBS News. The Eli Lilly drug, approved by the FDA in a record 50 days, removes the fasting requirement that forced patients to plan doses around empty-stomach windows.

Uninsured buyers will pay $149 for their first 30-day supply through TrumpRx coupons, then $199 for refills and $299 for future prescriptions, the official said. Americans with private insurance will pay about $25; Medicare recipients will pay roughly $50. Lilly will mirror those prices on its own Lilly Direct site, but the administration claims TrumpRx reaches more shoppers.

The FDA green-lit Foundayo under the agency’s priority-voucher program, shaving review time from the usual 10–12 months to two months. Lilly plans to ship the first bottles on April 6. The voucher system, announced last June, lets companies trade the fast-track ticket or sell it to another firm.

Unlike injectable GLP-1 drugs such as Wegovy or Zepbound, Foundayo is oral and does not require patients to skip meals before dosing, a barrier that doctors say causes many candidates to abandon therapy. The pill uses the same GLP-1 pathway to suppress appetite, but its absorption technology survives stomach acid, eliminating the need for needles or timed fasting.

A White House official told CBS that TrumpRx operates as a “one-stop shop” where consumers can compare all GLP-1 options, suggesting Foundayo’s arrival could pressure rivals to post lower prices on the same dashboard. The site, launched in February, already lists insulin, inhalers and several cancer drugs alongside real-time coupon offers.

Lilly will manufacture Foundayo at its Indianapolis campus and has pledged “millions of tablets” ready for the April launch, according to the FDA approval notice. The agency required a post-market study tracking heart-rate changes in patients over 65, results due in 2028.

People who avoided injections now have a cheaper, easier option, but the $149 cash price still tops the monthly cost of generic phentermine, which runs about $30 at big-box pharmacies. Doctors say the real test will be whether insurers add Foundayo to formularies and how quickly Lilly’s rivals answer with competing pills.